Anja Eberl
Helsinki, Finland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
The total gut mucosal and fecal bacterial load increases in successful treatment of inflammatory bowel disease with infliximab.
Journal: Microbiology spectrum
Published: July 07, 2025
Real-life treatment persistence and treatment outcomes of Finnish patients with inflammatory bowel disease receiving vedolizumab as first-line biological treatment.
Journal: Heliyon
Published: October 17, 2023
Higher serum infliximab concentrations during induction predict short-term endoscopic response in patients with inflammatory bowel disease.
Journal: European journal of gastroenterology & hepatology
Published: September 12, 2022
A nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn's disease patients in Finland.
Journal: Scandinavian journal of gastroenterology
Published: April 06, 2021
Bacterial and Fungal Profiles as Markers of Infliximab Drug Response in Inflammatory Bowel Disease.
Journal: Journal of Crohn's & colitis
Published: December 10, 2020
Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn's disease cohort.
Journal: European journal of gastroenterology & hepatology
Published: September 02, 2020
Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease.
Journal: Medicine
Published: January 09, 2020
Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).
Journal: Scandinavian journal of gastroenterology
Published: June 12, 2019
Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
Journal: Scandinavian journal of gastroenterology
Published: August 26, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026